ARTICLE | Product Development
New data refine populations, optimal doses for ADCs in NSCLC
AstraZeneca, Daiichi and Gilead present new data from TROP2- and HER2-targeting ADCs across lung cancers settings
September 11, 2023 11:17 PM UTC
Two antibody-drug conjugates against TROP2 are advancing toward use in the large indication of first-line non-small cell lung cancer (NSCLC), with new data presented at the IASLC 2023 World Conference on Lung Cancer pointing to possible safety and efficacy benefits over standard of care.
The latest findings from datopotamab deruxtecan (Dato-DXd), from partners AstraZeneca plc (LSE:AZN; NYSE:AZN) and Daiichi Sankyo Co. Ltd. (Tokyo:4568), and Trodelvy sacituzumab govitecan from Gilead Sciences Inc. (NASDAQ:GILD), suggest there may be little differentiation between the two ADCs in the indication. They also provide encouraging updates for the ADC class after a recent setback...